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Abstract The D-amino acid oxidase activator (DAOA)
protein regulates the function of D-amino oxidase (DAO),
an enzyme that catalyzes the oxidative deamination of
D-3,4-dihydroxyphenylalanine (D-DOPA) and D-serine.
D-DOPA is converted to L-3,4-DOPA, a precursor of
dopamine, whereas D-serine participates in glutamatergic
transmission. We hypothesized that DAOA polymorphisms
are associated with dopamine, serotonin and noradrenaline
turnover in the human brain. Four single-nucleotide
polymorphisms, previously reported to be associated with
schizophrenia, were genotyped. Cerebrospinal fluid (CSF)
samples were drawn by lumbar puncture, and the concen-
trations of the major dopamine metabolite homovanillic
acid (HVA), the major serotonin metabolite 5-hydroxyin-
doleacetic acid (5-HIAA) and the major noradrenaline
metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG)
were measured. Two of the investigated polymorphisms,
rs3918342 and rs1421292, were significantly associated
with CSF HVA concentrations. Rs3918342 was found to be
nominally associated with CSF 5-HIAA concentrations.
None of the polymorphisms were significantly associated
with MHPG concentrations. Our results indicate that
DAOA gene variation affects dopamine turnover in healthy
individuals, suggesting that disturbed dopamine turnover is
a possible mechanism behind the observed associations
between genetic variation in DAOA and behavioral phe-
notypes in humans.
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Introduction
The DAOA (D-amino acid oxidase activator gene) is located
on chromosome 13q34 and spans 29 Kb. This region,
spanning 5 Mb, was initially investigated by Chumakov
and colleagues, and two overlapping genes, DAOA (or
G72) and G30, transcribed in opposing directions, were
identified [7]. DAOA gene variation was initially associated
with schizophrenia [7], and during the past decade, this
association has been replicated in many subsequent studies
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(http://www.szgene.org) [2]. DAOA has also been associ-
ated with schizophrenia-related characteristics such as
frontal lobe volume change [16], susceptibility to meth-
amphetamine psychosis [26], response to antipsychotic
treatment [36] and progression of prodromal syndromes to
first episode psychosis [31]. Furthermore, DAOA has been
associated with other psychiatric disorders and phenotypes
such as major depression [40], bipolar disorder [38] and
bipolar disorder severity [8]. An animal study, using DAOA
transgenic mice, showed behavioral phenotypes associated
with psychosis, some of which could be reversed with
haloperidol [34].
The DAOA protein contains 153 amino acids and has
been detected in various parts of the central nervous system
(CNS), including amygdala, nucleus caudatus and spinal
cord [7]. DAOA has also been implicated in the regulation
of mitochondrial function and dendritic branching [28].
The DAOA protein was initially reported to behave as an
activator of porcine D-amino acid oxidase (DAO), whereas
more recent studies showed that DAOA modulates human
DAO function as a negative effector [7, 42].
DAO catalyzes the oxidative deamination of D-amino
acids, such as D-3,4-dihydroxyphenylalanine (D-DOPA)
and D-serine to a-keto acids. Thus, DAO deaminates
D-DOPA to its corresponding a-keto acid, which is then
transaminated to L-DOPA [24, 52]. L-DOPA then enters
the basic biosynthetic pathway to dopamine and homova-
nillic acid (HVA). Dopamine is converted to noradrenaline
by dopamine-beta-hydroxylase, and noradrenaline enters
its basic catabolic pathway and is degraded to 3-methoxy-
4-hydroxyphenylglycol (MHPG). Kinetic data show that
the maximal velocity for the oxidative deamination of
D-DOPA is much higher than for D-serine [24].
D-serine is an allosteric modulator of the N-methyl-D-
aspartate (NMDA)-type glutamate receptors (NMDAR)
[32], which have a modulatory site for D-serine. The
occupation of this site by D-serine is required for glutamate
to stimulate cation flow [19, 32]. Interaction between glu-
tamate and noradrenaline [9] suggests that DAOA may be
associated with noradrenaline via glutamatergic mecha-
nisms (Fig. 1).
There is also evidence of a bidirectional interaction
between NMDAR and the dopamine system. NMDAR
activation leads to enhanced recruitment of the dopamine
D1 receptor (DRD1) to the plasma membrane [37, 44].
Moreover, there is a direct protein–protein coupling
between DRD1 and NMDAR [10, 29, 37]. It has been
proposed that DRD1 and NMDAR early after their bio-
synthesis form heteromeric complexes, which are then
transported to plasma membrane as preformed units [30].
NMDA antagonists lead to an increase in midbrain dopa-
mine neuron firing rates [11], whereas striatal dopamine
release has been reported increased or decreased in some
studies [1, 39, 49]. A direct association between D-serine
and dopamine release has also been shown, as high doses
of D-serine attenuated amphetamine-induced dopamine
release [46].
Taken together, there are biochemical connections
between DAOA and the catecholamines dopamine and
noradrenaline, via two identified pathways, first via DAO,
D-serine and NMDAR, and secondly via DAO and
D-DOPA (Fig. 1). The concentration of the major seroto-
nin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in
cerebrospinal fluid (CSF) is strongly correlated with the
major dopamine metabolite HVA [13]. This suggests that
DAOA may also be associated with 5-HIAA (Fig. 1).
Given these biochemical and functional connections
between the DAOA protein and the monoamine metabo-
lites and the fact that studies in human twins and other
primates indicate that monoamine metabolite concentra-
tions are partly under genetic influence [17, 18, 35, 41], we
can speculate that the well-established associations
between DAOA and psychiatric phenotypes, described in
the first paragraph, may be mediated by disturbed mono-
amine turnover rates.
In the present study, we aim to investigate whether
DAOA polymorphisms are associated with dopamine,
serotonin and noradrenaline turnover in the human brain.
The concentrations of the major dopamine metabolite












D-amino acid oxidase activator (DAOA)                                          
D-amino oxidase (DAO)                                                                    
D-3,4-dihydroxyphenylalanine (D-DOPA)
L-3,4-dihydroxyphenylalanine (L-DOPA)
N-methyl-D-aspartate type glutamate receptor (NMDAR)                
3-methoxy-4-hydroxyphenylglycol (MHPG)
Homovanillic acid (HVA) 5-
hydroxyindoleacetic acid (5-HIAA)
Fig. 1 Biochemical and functional connections between D-amino
acid oxidase activator and cerebrospinal fluid monoamine metabolites
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major noradrenaline metabolite MHPG in CSF were used
as indirect indexes of the monoamine turnover.
Methods
Subjects
Unrelated healthy Caucasians, 78 men and 54 women,
participated in a longitudinal study. At the first interview,
when CSF was sampled, their mean ages ± standard
deviations (SD) were 27 ± 9 years, and all subjects were
found to be healthy. Of the women, 22 used oral contra-
ceptives at lumbar puncture, 29 did not, whereas data
were missing for three female participants. Except for oral
contraceptives, all subjects were drug-free at lumbar
puncture. Eight to twenty years after the first investiga-
tion, all subjects were re-interviewed to re-assess the
psychiatric morbidity as previously described [20, 23]. At
this interview, whole blood was drawn from all partici-
pants. At the second investigation, 43 of the subjects were
found to have experienced various DSM-III-R psychiatric
lifetime diagnoses. The study was conducted in accor-
dance with the Declaration of Helsinki and approved by
the Ethics Committee of the Karolinska University Hos-
pital. Informed consent was obtained from all the partic-
ipating subjects.
CSF monoamine metabolite concentrations
CSF samples (12.5 ml) were obtained by lumbar puncture
and analyzed as previously described [22, 45, 47]. Briefly,
the samples were drawn between 8 and 9 a.m. with the
subjects in the sitting or recumbent position, after at least
8 h of bed rest and absence of food intake or smoking.
5-HIAA, HVA and MHPG concentrations were measured
by mass fragmentography with deuterium-labeled stan-
dards. Back-length was defined as the distance between the
external occipital protuberance and the point of needle
insertion.
DNA analysis
Genomic DNA was extracted from whole blood [12]. Four
DAOA SNPs (rs2391191 or M15, rs778294 or M19,
rs3918342 or M23, rs1421292 or M24), previously repor-
ted to be associated with schizophrenia, were selected and
genotyped at the SNP Technology Platform at Uppsala
University and Uppsala University Hospital, Sweden
(http://www.genotyping.se), using the Illumina BeadSta-
tion 500GX and the 1536-plex Illumina Golden Gate assay
(Illumina Inc., San Diego, CA, USA) as previously
described [21].
Statistical analysis
Hardy–Weinberg (HW) equilibrium was tested using
Fisher’s exact test as implemented in PEDSTATS [51].
Linkage disequilibrium (D0 and r2) between SNP pairs was
determined with Haploview 4.0 [3]. Allele association
between DAOA SNPs and CSF monoamine metabolite
concentrations was tested with a general linear model (Proc
GLM, SAS/STAT software, version 9.1.3, SAS institute
Inc., Cary, NC, USA), where concentration was modeled as
a linear function of the allele count (of each SNP
separately) and one or more covariates (single-marker
association).
Covariates were selected by preliminary analysis
excluding genetic markers. That is, the effect of potentially
important confounders (back-length, weight, gender, age at
lumbar puncture and presence of a lifetime psychiatric
diagnosis) on CSF monoamine metabolite concentrations
was evaluated by forward stepwise selection, as previously
described [20]. Confounders that explained a significant
part of systematic variation in CSF concentrations
(P \ 0.1) were included as covariates in the genetic asso-
ciation analysis. Thus, back-length and presence of a life-
time psychiatric diagnosis were used as covariates in the
analysis of 5-HIAA and HVA concentrations, whereas
back-length and gender were included in the analyses of
MHPG. We tested the normal distribution of residuals with
the Anderson–Darling test, and residuals were approxi-
mately normally distributed after square root (5-HIAA,
HVA) and logarithmic (MHPG) transformations. Correc-
tion for multiple testing was performed through random
permutation of the four marker genotypes among individ-
uals and recalculation of the P values for the 12 tests for
each permuted data set (1,000 permuted data sets). The
corrected P value was then calculated as the fraction of
permutated data sets where the minimum P value from the
12 tests was equal to, or smaller than, the observed P value.
Moreover, rs3918342, showing the strongest association
with HVA, was selected for further analysis, applying a
dominant model of segregation.
Results
The mean (SD) concentrations of the three monoamine
metabolites were: HVA, 170.2 (72.3) nmol/L; 5-HIAA,
91.7 (37.4) nmol/L; MHPG, 41.6 (8.2) nmol/L. Two of the
investigated polymorphisms, rs3918342 (Fig. 2) and
rs1421292, were found to be significantly associated with
CSF HVA concentrations with corrected P values 0.013
and 0.043, respectively (Table 1). Rs3918342 was nomi-
nally associated with CSF 5-HIAA concentration, but this
association was not statistically significant when
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accounting for the number of tests conducted. No poly-
morphisms were associated with MHPG concentrations.
The two SNPs associated with HVA concentrations,
rs3918342 and rs1421292, are in strong linkage disequi-
librium (LD; r2 = 0.80) in Caucasians (HapMap, release
24). In the Scandinavian population, the two markers are in
almost complete LD (r2 = 0.99) [21], and thus, they cap-
tured the same association signal in this study. Conse-
quently, rs1421292 explained no additional variation in
HVA concentration (P = 0.95) on top of that explained by
rs3918342.
Carriers of the rs3918342 T allele (both C/T and T/T) had
50 nmol/l lower HVA mean concentrations compared with
C homozygotes; no difference in HVA mean concentrations
was found between C/T and T/T (Fig. 2). This pattern is
consistent with a dominant model of segregation (T allele
dominant), and as expected, this model resulted in a sub-
stantial decrease in the uncorrected P value for the associ-
ation between rs3918342 and HVA (from 0.0016 to 0.0001).
Discussion
In the present study, two DAOA polymorphisms,
rs3918342 and rs1421292, were significantly associated
with CSF HVA concentrations. Rs3918342 and rs1421292
are located 42 and 55 kbp from the 30 end of DAOA,
respectively, and are in strong linkage disequilibrium.
Rs3918342 and rs1421292 have not been ascribed any
functionality and were not found to be associated in strong
LD (r2 [ 0.6) with any SNP within the DAOA borders.
However, both were in strong LD with some intergenic
SNPs within 500 kbp from rs3918342 (HapMap release
24). The associated intergenic SNPs lack currently known
function or association with mental disorders.
During the past decades, a large number of CSF can-
didate markers, including the monoamine metabolite HVA,
have been investigated with regard to their relevance to
schizophrenia [48]. HVA concentrations have been repor-
ted to be significantly lower in drug-free schizophrenic
patients compared with controls [6, 50]. Both quetiapine
and olanzapine administrations have been associated with a
significant increase in CSF HVA [33, 43], whereas halo-
peridol withdrawal resulted in a significant decrease in CSF
HVA [5]. Thus, decreased HVA concentration appears to
be related to schizophrenia.
There are several studies suggesting that a locus located
near the 30 end of DAOA is associated with phenotypes
characteristic of schizophrenia or the progression of the
disease. For example, both rs3918342 and rs1421292 have
been associated with attention and memory impairments in
schizophrenic individuals [14]. Rs3918342 has been asso-
ciated with decreased hippocampal activation and
increased prefrontal activation in subjects at high genetic
risk of schizophrenia [15], as well as temporal lobe and
amygdala gray matter reduction [53]. Furthermore,
rs1421292 has been associated with brain activation in the
right middle temporal gyrus and the right precuneus in
healthy individuals [27]. Rs3918342 has been significantly
associated with schizophrenia in independent studies [4, 7,
25]. However, meta-analysis of rs3918342 suggests that the
association is restricted to populations of Caucasian origin
and that the effect size is small (odds ratio = 1.03, non-
significant; http://www.szgene.org) [2].
We found the TT genotype of rs3918342 to be strongly
associated with decreased HVA concentrations, and we
note that it is also this genotype that has been associated
with attention and memory impairments in schizophrenic
individuals [14], decreased hippocampal activation and
increased prefrontal activation in subjects at high genetic
risk of schizophrenia [15] as well as temporal lobe and
amygdala gray matter reduction in bipolar patients [53].
Thus, it is possible that a disturbed dopamine turnover,
reflected by decreased HVA levels, may be a mechanism
behind one or several of the cognitive, neurological and
brain morphological phenotypes previously associated with
the rs3918342 TT genotype.
In conclusion, our results suggest that DAOA gene
variation significantly affects dopamine turnover in CNS of
healthy controls. Further research is needed in order
to replicate our findings in healthy controls and, moreover,
to find out whether the present associations can also be
observed in schizophrenia and other psychiatric disorders.
Fig. 2 Cerebrospinal fluid (CSF) homovanillic acid (HVA) concen-
tration in healthy subjects as a function of the number of rs3918342
T-alleles (corrected P value = 0.013). Least square means and
standard errors are given
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